What Did You Miss at the 4th ADC Linker & Conjugation Summit?
The 4th ADC Linker & Conjugation Summit was designed to equip chemistry and bioconjugation teams with the tools needed to design safer, more stable, and clinically translatable ADCs.
Attendees joined 80+ discovery chemists, protein engineers, and translational leaders in Boston for three days of deep technical exploration into linker architecture, conjugation precision, and platform scalability.
This year's agenda tackled the field’s most urgent challenges, including preventing premature payload release, reducing off-target toxicity, overcoming hydrophobicity and aggregation, and enabling homogeneous high-DAR and dual-payload constructs.
You would have gained practical guidance on engineering orthogonal conjugation systems, leveraging enzymatic and glycan-directed strategies, adopting next-generation linker chemistries beyond maleimides, and integrating computational modeling to de-risk candidate selection.
With 25+ expert-led case studies and focused workshops, this summit provided the technical depth required to optimize linker stability, control DAR distribution, enhance pharmacokinetics, and confidently advance next-generation ADC platforms.
Unmissable Event Highlights:
Reduce Off-Target Toxicity Through Smarter Linker Design
Attendees explored hydrophilicity-masking, charge-shielding, cleavable, and stimuli-responsive linker architectures to widen the therapeutic window and improve plasma stability with SKYMAB Biotherapeutics & AbTx
Engineer Homogeneous, Site-Specific Conjugates
Attendees implemented enzymatic, glycan-directed, and pyridazinedione-based conjugation technologies to achieve precise DAR control and scalable manufacturing with Biohaven & Hexagon Bio
Architect Dual-Payload ADCs to Overcome Resistance
You would have leveraged orthogonal chemistry and modular linker systems to enable stable, spatially controlled dual-loading strategies with Araris Biotech & Crossbridge Bio
Unlock High-DAR & Novel Modalities
Attendees mitigated hydrophobicity-driven aggregation and enable degrader-antibody conjugates through advanced linker scaffolds and solubilizing strategies with Exelixis & Iksuda Therapeutics
Future-Proof ADC Platform Design
You would have integrated computational modeling, analytical insight, and translational data to accelerate decision-making and de-risk next-generation development with Oncoprecision & Aarvik Therapeutics
New Companies for 2026:
Explore the 2026 Event Guide
The 4th ADC Linker & Conjugation Summit was the only dedicated platform focused solely on solving the chemistry challenges underpinning next-generation ADC design.
Highlights Included:
- 20+ expert speakers from leading big pharma and biotech organizations advancing linker and conjugation innovation
- Actionable, technical insights into site-specific, enzymatic, glycan-directed, click-chemistry, and pyridazinedione-based conjugation strategies
- Case studies on dual-payload ADCs, high-DAR constructs, degrader-antibody conjugates, and orthogonal conjugation platforms
- 2 interactive pre-conference workshops bridging chemistry with PK/PD and translational performance
Explore the 2026 Agenda
Attendees gained actionable insights from expert-led sessions on advanced linker design, next-generation bioconjugation chemistries, and strategies to minimize off-target toxicity.
Partner With Us
Connect with 80+ ADC linker and conjugation leaders actively seeking solutions to advance the design, production and testing their of next-generation ADC technologies.
Join ADC Linker & Conjugation Experts
Network with senior scientists and highly technical experts working at the cutting edge of ADC chemistry, alongside key decision makers from leading biopharma organizations, in dedicated sessions designed to build meaningful collaborations.